12,594 trials (keyword fallback)
Graft Versus Host Disease
Primary: Percentage of Participants With Incidence of Grade II-IV GVHD — 33; 31; 21 Percentage of participants
Hematologic Malignancies · Graft vs Host Disease
Primary: 100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) — 22 percentage of participants
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Acute Lymphoblastic Leukemia · ALL · Acute Myelogenous Leukemia
Primary: Rate of Dose Limiting Toxicities — 0.045 proportion of participants of DLT
Graft vs Host Disease
Primary: Percentage of Patients That Respond to Treatment — 65 percentage of patients
Graft Versus Host Disease
Primary: Percentage of Patients Alive at 6 Months — 83 percentage of patients
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Leukemia · Myelodysplastic Syndrome · Non-Hodgkin's Lymphoma
Primary: Death From GVHD — 4 participants
Graft vs Host Disease · Graft-Versus-Host Disease
Primary: Overall Response at 6 Months — 0; 0; 7; 9 Participants
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Acute Graft vs Host Disease · Allogeneic Bone Marrow Transplantation · Adverse Effects
Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Graft vs Host Disease · Hematopoietic Stem Cell Transplantation
Primary: Percentage of Patients With Grade II-IV Acute GvHD by Day +100 Following Transplant — 94.4 percentage of participants